Role of B7‐H3 in predicting response to neoadjuvant chemotherapy in muscle‐invasive bladder cancer
Abstract Background Neoadjuvant platinum‐based chemotherapy offers a modest survival advantage in muscle‐invasive bladder cancer (MIBC) for patients with pathologic response. B7‐H3 (CD276), an immune checkpoint overexpressed in various cancers, including urothelial‐cell carcinoma (UCC), has been ass...
Saved in:
Main Authors: | Ekamjit S. Deol, Reza Nabavizadeh, Roxane R. Lavoie, Mihai G. Dumbrava, Edlira Horjeti, Prabin Thapa, John C. Cheville, Igor Frank, Fabrice Lucien |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-11-01
|
Series: | BJUI Compass |
Subjects: | |
Online Access: | https://doi.org/10.1002/bco2.418 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01) -
Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01) -
COMBINED TREATMENT OF LOCALLY-ADVANCED BLADDER CANCER
by: I. V. Chernyshev, et al.
Published: (2016-01-01) -
Integrated enhanced recovery after surgery protocol in radical cystectomy for bladder tumour—A retroprospective study
by: Waseem Ashraf, et al.
Published: (2024-11-01) -
COVID-19 impact on bladder cancer treatment
by: Fabrício Kaminagakura, et al.
Published: (2024-01-01)